- Home
- VTYX
as 12-20-2024 3:44pm EST
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 184.6M | IPO Year: | 2021 |
| Target Price: | $8.40 | AVG Volume (30 days): | 2.3M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.67 - $11.48 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Ventyx Biosciences Inc. (VTYX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nuss John | VTYX | CHIEF SCIENTIFIC OFFICER | Dec 17 '24 | Sell | $2.26 | 13,161 | $29,682.00 | 485,701 | |
| Mohan Raju | VTYX | CEO AND PRESIDENT | Nov 22 '24 | Buy | $1.92 | 500,000 | $959,889.18 | 1,913,276 |
Latest Ventyx Biosciences Inc. News
VTYX Breaking Stock News: Dive into VTYX Ticker-Specific Updates for Smart Investing
Simply Wall St.
8 days ago
Ventyx Biosciences Insiders Land Bargain With Gains Of US$180k
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 11/26/2024
Simply Wall St.
a month ago
Ventyx Biosciences, Inc.'s (NASDAQ:VTYX) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures
TipRanks
a month ago
Ventyx Biosciences Reports Q3 Financial Results and Pipeline Progress
GlobeNewswire
a month ago
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
MT Newswires
a month ago
Oppenheimer Trims Ventyx Biosciences Price Target to $9 From $10, Maintains Outperform Rating
GlobeNewswire
a month ago
Ventyx Biosciences Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Progress
TipRanks
2 months ago
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts
Compare VTYX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTYX Ventyx Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.